363179-57-1

Basic information

• Product Name: 2,3-DIFLUOROPHENYL ISOTHIOCYANATE
• Synonyms: 2,3-DIFLUOROPHENYL ISOTHIOCYANATE;Benzene, 1,2-difluoro-3-isothiocyanato- (9CI);1,2-Difluoro-3-isothiocyanatobenzene
• CAS NO: 363179-57-1
• Molecular Formula: C₇H₃F₂NS
• Molecular Weight: 171.17
• Product Categories: ISOTHIOCYANATE;Fluorine series
• Mol File: 363179-57-1.mol

Chemical Properties

• Boiling Point: 49-50°C/0.4mm
• Flash Point: 95℃
• Appearance: /
• Density: 1.26
• Vapor Pressure: 0.0853mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 2,3-DIFLUOROPHENYL ISOTHIOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIFLUOROPHENYL ISOTHIOCYANATE(363179-57-1)
• EPA Substance Registry System: 2,3-DIFLUOROPHENYL ISOTHIOCYANATE(363179-57-1)

Safety Data

• Hazardous Substances Data: 363179-57-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Difluorophenyl Isothiocyanate is used as a reagent for introducing the isothiocyanate functional group into other molecules, particularly in the preparation of various pharmaceuticals. It serves as a building block in the synthesis of diverse chemical compounds and bioactive molecules, contributing to the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 2,3-Difluorophenyl Isothiocyanate is also utilized as a reagent for the synthesis of various agrochemicals. Its ability to introduce the isothiocyanate functional group into molecules makes it a valuable component in the creation of pesticides and other agricultural chemicals.

InChI:InChI=1/C7H3F2NS/c8-5-2-1-3-6(7(5)9)10-4-11/h1-3H

Upstream product

• 463-71-8 thiophosgene 
• 4519-40-8 2,3-difluoroanilline 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 

Downstream Products

• 611214-77-8 4-({2-[(2,3-difluorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl}oxy)-N-methylpyridine-2-carboxamide 

Relevant articles and documents

Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses

There are currently no drugs available for the treatment of enterovirus (EV)-induced acute and chronic diseases such as the common cold, meningitis, encephalitis, pneumonia, and myocarditis with or without consecutive dilated cardiomyopathy. Here, we report the discovery and characterization of pyrazolopyrimidines, a well-tolerated and potent class of novel EV inhibitors. The compounds inhibit the replication of a broad spectrum of EV in vitro with IC50 values between 0.04 and 0.64 μM for viruses resistant to pleconaril, a known capsid-binding inhibitor, without affecting cytochrome P450 enzyme activity. Using virological and genetics methods, the viral capsid was identified as the target of the most promising, orally bioavailable compound 3-(4-trifluoromethylphenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine (OBR-5-340). Its prophylactic as well as therapeutic application was proved for coxsackievirus B3-induced chronic myocarditis in mice. The favorable pharmacokinetic, toxicological, and pharmacodynamics profile in mice renders OBR-5-340 a highly promising drug candidate, and the regulatory nonclinical program is ongoing. Curing the common cold! A cluster of pyrazolopyrimidines with potent broad-spectrum activity against enteroviruses was discovered. Extensive structure-property relationship analyses led to the identification of 3-(4-trifluoromethyl-phenyl)amino-6-phenylpyrazolo[3,4-d]pyrimidine-4-amine, shown to be a blocker of the viral capsid protein, as a lead compound for drug development with favorable physicochemical, pharmacokinetic, and toxicological properties.

Facile and versatile synthesis of alkyl and aryl isothiocyanates by using triphosgene and cosolvent

A mild and efficient method for the conversion of alkyl and aryl amines to isothiocyanates via dithiocarbamates has been developed using (CH 3)2CO-CS2 as co-solvent and triphosgene as dehydrosulfurization reagent. High yields, mild reaction conditions and excellent functional group compatibility make it become a versatile synthetic method for the preparation of isothiocyanates compared with reported methods. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]

Il-8 receptor anatagonists

This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).